Immix Biopharma Inc IMMX

Healthcare Biotechnology

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

NDAQ:IMMX - Post by User

Immix Biopharma Inc

<< Previous

Bullboard Posts

Post by whytestockson Feb 08, 2024 11:15pm

68 Views

Post# 35871634

Immix Biopharma Announces Closing of $15 Million Public Offe

NEWS: $IMMX Immix Biopharma Announces Closing of $15 Million Public Offering of Common StockLOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology,...IMMX - Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

<< Previous

Bullboard Posts

Tilray Brands launches health-conscious cannabis drinks